



Buparvaquone Injection

Butalex® Injection

NOT FOR HUMAN USE
FOR ANIMAL TREATMENT ONLY

Warning : To be sold by retail on
the prescription of a Registered
Veterinary Practitioner only.

Presentation

Butalex is a clear red-brown solution for intramuscular injection.

Composition

Each 1 ml contains 50 mg buparvaquone.

Indications

Butalex is highly effective in the treatment of Theileriosis (East Coast fever, Corridor Disease, tropical theileriosis etc.) in cattle, caused by strains of *Theileria parva parva*, *T. parva bovis*, *T. parva lawrencei*, *T. annulata*, *T. mutans* and *T. orientalis*. Butalex is effective against both the schizont and piroplasm stages of *Theileria* species. Butalex is indicated for treatment of animals with apparent clinical signs, for metaphylactic treatment during the incubation period and for prophylactic treatment of contact animals.

Amounts to be administered and administration route

To ensure a correct dosage body weight should be determined as accurately as possible. The recommended dose is 2.5 mg buparvaquone per kg body weight (corresponding to 1 ml Butalex per 20 kg body weight) by intramuscular route in the deep neck muscle. If the dose volume exceeds 10 ml, the dose should be divided and administered to different sites. Generally, one dose is sufficient for the treatment. In heavy cases, a second treatment (at the same dose) may be required 48-72 hours after the first dosing.

Special warnings for each target species

Butalex is not indicated in the treatment of other blood parasites (Babesiosis, Anaplasmosis).

As Theileriosis can seriously impair the immune system of affected animals, the animals are susceptible to secondary infections.

Anaemia is a frequent characteristic of *Theileria spp.* infections, particularly those caused by *T. annulata*, *T. sergenti* and *T. mutans*. In such cases supportive treatment may be required.

In case of severe Theileriosis, relapses may occur, requiring further treatment. Recovered animals will develop homologous immunity. However any subsequent infections with antigenically unrelated species or strains of *Theileria* may require further treatment. In case of recurrence or re-infection with another strain, the treatment should be repeated.

Concurrent treatment against the vector parasites using suitable ectoparasiticides is recommended.

As Theileriosis has severe depressant effects on the immune system, any vaccination should be delayed until the animal has recovered.

Special precautions for use

Special precautions for use in animals

Do not administer by either intravenous or subcutaneous routes.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid contact with skin and wash hands after use. In case of contact with skin, wash with soap and water. Clothing contaminated with the veterinary medicinal product should be changed.

Do not eat, drink or smoke during administration.

Adverse reactions (frequency and seriousness)

Localised, painless, oedematous swelling may occasionally be seen at the injection site.

Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy.

Therefore, the use is not recommended during pregnancy.

Contraindications: Not Known

Overdose (symptoms, emergency procedures, antidotes), if necessary

No data available.

Interaction with other medicinal products and other forms of interaction

None known.

Pharmacodynamic properties

Buparvaquone is a hydroxynaphthoquinone antiprotozoal compound. It is effective against schizont and piroplasm stages of *Theileria* species. Buparvaquone is thought to interfere specifically with parasites mitochondrial electron transport.

Pharmacokinetic particulars

Buparvaquone is absorbed gradually from the injection site, distributed into the body and persist at schizont-inhibitory concentrations in blood plasma for at least 7 days. A large portion of buparvaquone is excreted mainly through the faeces and only a small portion through the urine

List of excipients

Sorbitan Mono-Oleate
Fractionized Coconut Oil
N-methyl-2-pyrrolidone

Withdrawal Period

Meat: 42 days and Milk: 48 hours

Major incompatibilities

None known.

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Storage recommendations

Store below 25°C
Protect from light

PRESENTATION - 20 ml VIAL

Manufactured by

Vet Pharma Friesoythe GmbH
Sedelsberger Str.2,
26169 Friesoythe,
Germany.

Imported & Marketed by

Intervet India Pvt. Ltd.
Bldg. No. B-1, Godown No.12 to 16, Ground
Floor & Godown No.12-A to 17-A First Floor,
House No. 233, Sagar Complex, Owali,
Bhiwandi, Thane -421302, Maharashtra, India.



MSD
Animal Health



232959 R2

PSC020D03_01_R1
105 x 296 mm

Moved to repository by KETELAAX 14:Apr:2025 07:26